Myocardial preconditioning and cardioprotection by volatile anaesthetics

Journal of Cardiovascular Medicine

Volumn 7, Issue 2, 2006, Pages 86-95

  Siracusano, Luca ^a,b   Girasole, Viviana ^a   Alvaro, Simona ^a   Chiavarino, Nunziata Di Marco ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE   (Italy)

Author keywords

Cardioprotection; Postconditioning; Preconditioning

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 HYDROXYDECANOIC ACID; CYCLOOXYGENASE 2 INHIBITOR; CYTOSKELETON PROTEIN; DIAZOXIDE; ENFLURANE; GAP JUNCTION PROTEIN; GLIBENCLAMIDE; INHALATION ANESTHETIC AGENT; ISOFLURANE; MITOCHONDRIAL PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NALOXONE; NICORANDIL; NITRIC OXIDE; POTASSIUM CHANNEL; PROTEIN KINASE C; SULFONYLUREA DERIVATIVE; ANESTHETIC AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN;

CELL DEATH; ENZYME PHOSPHORYLATION; HEART INFARCTION SIZE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; NEUROPROTECTION; NONHUMAN; REVIEW; APOPTOSIS; CELL JUNCTION; CYTOSKELETON; HEART INFARCTION PREVENTION; HEART MITOCHONDRION; METABOLISM; NURSE ANESTHETIST; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ANESTHETICS; APOPTOSIS; CONNEXINS; CYTOSKELETON; GAP JUNCTIONS; GTP-BINDING PROTEINS; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MITOCHONDRIA, HEART; MYOCARDIUM; NURSE ANESTHETISTS; PHOSPHORYLATION; POTASSIUM CHANNELS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

EID: 33646848050     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/01.JCM.0000199792.32479.ce     Document Type: Review

References (101)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischaemia: a delay of lethal cell injury in ischaemic myocardium. Circulation 1986; 74:1124-1136.
2. Li GC, Vasquez JA, Gallagher KP, Lucchesi BR. Myocardial protection with preconditioning. Circulation 1990; 82:609-619.
3. Cohen MV, Baines CP, Downey JM. Ischemic preconditioning: from adenosine receptor of KATP channel. Annu Rev Physiol 2000; 62:79-109.
4. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003; 83:1113-1151.
5. Ovize M, Aupetit J, Rioufoul G, Loufoua J, Andre-Fouet X, Minaire Y, Faucon G. Preconditioning reduces infarct size but accelerates time to ventricular fibrillation in ischemic pig heart. Am J Physiol 1995; 269:H72-H79.
6. Post H, Heusch G. Ischemic preconditioning. Experimental facts and clinical perspective. Min Cardioangiol 2002; 50:569-605.
7. Kawamura S, Yoshida K, Miura T, Mizukami Y, Matsuzaki M. Ischemic preconditioning translocates PKC-delta and -epsilon, which mediate functional protection in isolated rat heart. Am J Physiol 1998; 27:H2266-H2271.
8. Sharma A, Singh M. Possible mechanism of cardioprotective effect of ischaemic preconditioning in isolated rat heart. Pharmacol Res 2000; 41:635-640.
9. Yang X-M, Sato H, Downey JM, Cohen MV. Protection of ischemic preconditioning is dependent upon a critical timing sequence of protein kinase C activation. J Mol Cell Cardiol 1997; 29:991-999.
10. Vahlhaus C, Schulz R, Post H, Rose J, Heusch G. Prevention of ischemic preconditioning only by combined inhibition of protein kinase C and protein tyrosine kinase in pigs. J Mol Cell Cardiol 1998; 30:197-209.
11. Schulz R. A new paradigm: cross talk of protein kinases during reperfusion saves life! Am J Physiol Heart Circ Physiol 2005; 288:H1-H2.
12. Hausenloy DJ, Mocanu MM, Yellon DM. Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res 2004; 63:305-312.
13. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of 'modified reperfusion' protects the myocardium by activating the phosphatidylinositol3-kinase-Akt pathway. Circ Res 2004; 95:230-232.
14. Argaud L, Roesch OG, Raisky O, Loufouat J, Robert D, Ovize M. Postconditioning inhibits mitochondrial permeability transition. Circulation 2005; 111:194-197.
15. Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Ann Rev Physiol 1999; 61:337-362.
16. + channel in the mitochondrial inner membrane. Nature 1991; 352:244-247.
17. 2+ transients that modulate nuclear function. Proc Natl Acad Sci 2002; 99:9544-9549.
18. Zhuo ML, Huang Y, Liu DP, Liang CC. KATP channel: relation with cell metabolism and role in the cardiovascular system. Int J Biochem Cell Biol 2005; 37:751-764.
19. + channels in cardiac muscle. Nature 1983; 305:147-148.
20. + blocker dofetilide. Am J Physiol 1996; 271:H1207-H1214.
21. + channels. Possible mechanism of cardioprotection. Circ Res 1997; 81:1072-1082.
22. Sasaki N, Sato T, Ohler A, O'Rourke B, Marban E. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 2000; 101:439-445.
23. Kowaltowski AJ, Seetharaman S, Paucek P, Garlid KD. Bioenergetic consequences of opening the ATP-sensitive K + channel of heart mitochondria. Am J Physiol Heart Circ Physiol 2001; 280:H649-H657.
24. Liu Y, Sato T, O'Rourke B, Marban E. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 1998; 97:2463-2469.
25. Vanden Hoek T, Becker LB, Shao ZH, Li CQ, Schumacker PT. Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion. Circ Res 2000; 86:541-548.
26. Fryer RM, Hsu AK, Gross GJ. Mitochondrial K (ATP) channel opening is important during index ischemia and following myocardial reperfusion in ischemic preconditioned rat hearts. J Mol Cell Cardiol 2001; 33:831-834.
27. + channels in cardiac myocytes: a mechanism of the cardioprotective effect and modulation by protein kinase A. Circulation 2005; 111:198-203.
28. Duchen MR. Contributions of mitochondria to animal physiology: from homeostatic sensor to calcium signalling and cell death. J Physiol 1999; 516:1-17.
29. Duchen MR. Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol Aspects Med 2004; 25:365-451.
30. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol 2003; 552:335-344.
31. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999; 341:233-249.
32. Hausenloy D, Wynne A, Duchen M, Yellon D. Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection. Circulation 2004; 109:1714-1717.
33. Takemura G, Hisayoshi F. Role of apoptosis in remodeling after myocardial infarction. Pharmacol Therap 2004; 104:1-16.
34. Segretain D, Falk MM. Regulation of connexin biosynthesis, assembly, gap junction formation, and removal. Biochim Biophys Acta 2004; 1662:3-21.
35. Saez JC, Berthoud VM, Branes MC, Martinez AD, Beyer EC. Plasma membrane channels formed by connexins: their regulation and functions. Physiol Rev 2003; 83:1360-1400.
36. Garcìa-Dorado D, Rodrìguez-Sinovas A, Ruiz-Meana M. Gap junction-mediated spread of cell injury and death during myocardial ischemia-reperfusion. Cardiovasc Res 2004; 61:386-401.
37. Schulz R, Heusch G. Connexin 43 and ischemic preconditioning. Cardiovasc Res 2004; 62:335-344.
38. Garcia-Dorado D, Ruiz-Meana M, Padilla F, Rodriguez-Sinovas A, Mirabet M. Gap junction-mediated intercellular communication in ischemic preconditioning. Cardiovasc Res 2002; 55:456-465.
39. Schwanke U, Konietzka I, Duschin A, Li X, Schulz R, Heusch G. No ischemic preconditioning in heterozygous connexin 43-deficient mice. Am J Physiol Heart Circ Physiol 2002; 283:H1740-H1742.
40. Padilla F, Garcia-Dorado D, Rodriguez-Sinovas A, Ruiz-Meana M, Inserte J, Soler-Soler J. Protection afforded by ischemic preconditioning is not mediated by effects on cell-to-cell electrical coupling during myocardial ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2003; 285:H1909-H1916.
41. Li X, Heinzel FR, Boengler K, Schulz R, Heusch G. Role of connexin 43 in ischemic preconditioning does not involve intercellular communication through gap junctions. J Mol Cell Cardiol 2004; 36:161-163.
42. Li H, Brodsky S, Kumari S, Valiunas V, Brink P, Kaide J, et al. Paradoxical overexpression and translocation of connexin 43 in homocysteine-treated endothelial cells. Am J Physiol Heart Circ Physiol 2001; 282:H2124-H2133.
43. Boengler K, Dodoni G, Rodriguez-Sinovas A, Cabestrero A, Ruiz-Meana M, Gres P, et al. Connexin 43 in cardiomyocyte mytochondria and its increase by ischemic preconditioning. Cardiovasc Res 2005; 67:234-244.
44. Ganote C, Armstrong S. Ischaemia and the myocyte cytoskeleton: review and speculations. Cardiovasc Res 1993; 27:1387-1403.
45. Sakamoto K, Urushidani T, Nagao T. Translocation of HSP27 to sarcomere induced by ischemic preconditioning in isolated rat hearts. Biochem Biophys Res Commun 2000; 269:137-142.
46. Baxter GF, Ferdinandy P. Delayed preconditioning of myocardium: current perspectives. Basic Res Cardiol 2001; 96:329-344.
47. Bolli R, Bhatti ZA, Tang XL, Qiu Y, Zhang Q, Guo Y, Jadoon AK. Evidence that late preconditioning against myocardial stunning in conscious rabbits is triggered by the generation of nitric oxide. Circ Res 1997; 81:42-52.
48. Bolli R. The late phase of preconditioning. Circ Res 2000; 87:972-983.
49. Nichols TC. NF-kB and reperfusion injury. Drug News Perspect 2004; 17:99-104.
50. Cope DK, Impastato WK, Cohen MV, Downey JM. Volatile anesthetics protect the ischemic rabbit myocardium from infarction. Anesthesiology 1997; 86:699-709.
51. Kersten JR, Brayer AP, Pagel PS, Tesmer JP, Warltier DC. Perfusion of ischemic myocardium during anesthesia with sevoflurane. Anesthesiology 1994; 81:995-1004.
52. ATP channels in vivo. Anesthesiology 1999; 90:246-256.
53. Ca) channels in vivo. Anesthesiology 2002; 97:725-731.
54. Lochner A, Harper IS, Salie R, Genade S, Coetzee AR. Halothane protects the isolated rat myocardium against excessive total intracellular calcium and structural damage during ischemia and reperfusion. Anesth Analg 1994; 79:226-233.
55. Kersten JR, Schmeling TJ, Pagel PS, Gross GJ, Warltier DC. Isoflurane mimics ischemic preconditioning via activation of K (ATP) channels: reduction of myocardial infarct size with an acute memory phase. Anesthesiology 1997; 87:361-370.
56. Cason BA, Gamperl AK, Slocum RE, Hickey R. Anesthetic-induced preconditioning: previous administration of isoflurane decreases myocardial infarct size in rabbits. Anesthesiology 1997; 87:1182-1190.
57. Kato R, Foex P. Myocardial protection by anesthetic agents against ischemia-reperfusion injury: an update for anesthesiologists. Can J Anaesth 2002; 49:777-791.
58. Zaugg M, Lucchinetti E, Uecker M, Pasch T, Schaub MC. Anaesthetics and cardiac preconditioning. Part I. Signalling and cytoprotective mechanisms. Br J Anaesth 2003; 91:551-565.
59. Zaugg M, Lucchinetti E, Garcia C, Pasch T, Spahn DR, Schaub MC. Anaesthetics and cardiac preconditioning. Part II. Clinical implications. Br J Anaesth 2003; 91:566-576.
60. Foex P. Inhalation anaesthesia and myocardial preconditioning. Minerva Anesthesiol 2003; 69:483-494.
61. Tanaka K, Ludwig LM, Kersten JR, Pagel PS, Warltier DC. Mechanisms of cardioprotection by volatile anesthetics. Anesthesiology 2004; 100:707-721.
62. Stowe DF, Kevin LG. Cardiac preconditioning by volatile anesthetic agents: a defining role for altered mitochondrial bioenergetics. Antioxid Redox Signal 2004; 6:439-448.
63. Hanley PJ, Ulrich Brandt JR, Daut J. Halothane, isoflurane and sevoflurane inhibit NADH: ubiquinone oxidoreductase (complex I) of cardiac mitochondria. J Physiol 2002; 544:687-693.
64. Kayser E-B, Morgan P, Sedensky M. GAS-1: a mitochondrial protein controls sensitivity to volatile anesthetics in the nematode Caenorhabditis elegans. Anesthesiology 1999; 90:545-554.
65. Morgan PG, Charles CL, Sedensky MM. Mitochondrial defects and anesthetic sensitivity. Anesthesiology 2002; 96:1266-1270.
66. Chiari PC, Bienengraeber MW, Pagel PS, Krolikowski JG, Kersten JR, Warltier DC. Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: evidence for anesthetic-induced postconditioning in rabbits. Anesthesiology 2005; 102:102-109.
67. Uecker M, da Silva R, Grampp T, Pasch T, Schaub MC, Zaugg M. Translocation of protein kinase C isoforms to subcellular targets in ischemic and anesthetic preconditioning. Anesthesiology 2003; 99:138-147.
68. da Silva R, Grampp T, Pasch T, Schaub MC, Zaugg M. Differential activation of mitogen-activated protein kinases in ischemic and anesthetic preconditioning. Anesthesiology 2004; 100:59-69.
69. Kehl F, Pagel PS, Krolikowski JG, Gu W, Toller W, Warltier DC, Kersten JR. Isoflurane does not produce a second window of preconditioning against myocardial infarction in vivo. Anesth Analg 2002; 95:1162-1168.
70. Sergeev P, da Silva R, Lucchinetti E, Zaugg K, Pasch T, Schaub MC, Zaugg M. Trigger-dependent gene expression profiles in cardiac preconditioning: evidence for distinct genetic programs in ischemic and anesthetic preconditioning. Anesthesiology 2004; 100:474-488.
71. He DS, Burt JM. Mechanism and selectivity of the effects of halothane on gap junction channel function. Circ Res 2000; 86:E104-E109.
72. Alcindor D, Krolikowski JG, Pagel PS, Warltier DC, Kersten JR. Cyclooxygenase-2 mediates ischemic, anesthetic, and pharmacologic preconditioning in vivo. Anesthesiology 2004; 100:547-554.
73. Zhong C, Zhou Y, Liu H. Nuclear factor kB and anesthetic preconditioning during myocardial ischemia-reperfusion. Anesthesiology 2004; 100:540-546.
74. Riess ML, Stowe DF, Warltier DC. Cardiac pharmacological preconditioning with volatile anesthetics: from bench to bedside? Am J Physiol Heart Circ Physiol 2004; 286:H1603-H1607.
75. Laskey WK. Beneficial impact of preconditioning during PTCA on creatine kinase release. Circulation 1999; 99:2085-2089.
76. + channel blocker. Circulation 1994; 90:700-705.
77. Tomai F, Crea F, Gaspardone A, Versaci F, Ghini AS, Ferri C, et al. Effects of naloxone on myocardial ischemic preconditioning in humans. J Am Coll Cardiol 1999; 33:1863-1869.
78. Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, et al. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation 1995; 91:37-45.
79. Marber MS, Joy MD, Yellon DM. Is warm-up in angina ischaemic preconditioning? Br Heart J 1994; 72:213-215.
80. Tomai F. Warm up phenomenon and preconditioning in clinical practice. Heart 2002; 87:99-100.
81. Vaage J, Valen G. Preconditioning and cardiac surgery. Ann Thorac Surg 2003; 75:S709-S714.
82. Jenkins DP, Pugsley WB, Alkhulaifi AM, Kemp M, Hooper J, Yellon DM. Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery. Heart 1997; 77:314-318.
83. Kaukoranta PK, Lepojarvi MP, Ylitalo KV, Kiviluoma KT, Pauhkurinen KJ. Normothermic retrograde blood cardioplegia with or without preceding ischemic preconditioning. Ann Thorac Surg 1997; 63:1268-1274.
84. Wei MX, Kuukasjarvi P, Laurikka J, Pehkonen E, Kaukinen S, Laine S, Tarkka M. Cytokine responses in patients undergoing coronary artery bypass surgery after ischemic preconditioning. Scand Cardiovasc J 2001; 35:142-146.
85. Wu Z-K, Pehkonen E, Laurikka J, Kaukinen L, Honkonen EL, Kaukinen S, et al. The protective effects of preconditioning decline in aged patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2001; 122:972-978.
86. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359:1269-1275.
87. Julier K, da Silva R, Garcia C, Frascarolo P, Zollinger A, Chassot PG, et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology 2003; 98:1315-1327.
88. Garcia C, Julier K, Bestmann L, Zollinger A, von Segesser LK, Pasch T, et al. Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery. Br J Anaesth 2005; 94:159-165.
89. Belhomme D, Peynet J, Louzy M, Launay JM, Kitakaze M, Menasche P. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation 1999; 100:II340-II344.
90. Haroun-Bizri S, Khoury SS, Chehab IR, Kassas CM, Baraka A. Does isoflurane optimize myocardial protection during cardiopulmonary bypass? J Cardiothorac Vasc Anesth 2001; 15:418-421.
91. Tomai F, De Paulis R, Penta de Peppo A, Colagrande L, Caprara E, Polisca P, et al. Beneficial impact of isoflurane during coronary bypass surgery on troponin I release. G Ital Cardiol 1999; 29:1007-1014.
92. Penta de Peppo A, Polisca P, Tomai F, Tomai F, De Paulis R, Turani F, et al. Recovery of LV contractility in man is enhanced by preischemic administration of enflurane. Ann Thorac Surg 1999; 68:112-128.
93. Pouzet B, Lecharny JB, Paquin S, Kitakaze M, Mantz J, Menache P. Is there a place for preconditioning during cardiac operation in humans? Ann Thorac Surg 2002; 73:843-848.
94. Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci 2003; 26:248-254.
95. Koti RS, Seifalian AM, Davidson BR. Protection of the liver by ischemic preconditioning: a review of mechanisms and clinical applications. Dig Surg 2003; 20:383-396.
96. McLaren AJ, Friend PJ. Trends in organ preservation. Transpl Int 2003; 16:701-708.
97. Kosieradzki M, Ametani M, Southard JH, Mangino MJ. Is ischemic preconditioning of the kidney clinically relevant? Surgery 2003; 133:81-90.
98. Halkos ME, Kerendi F, Corvera JS, Wang NP, Kin H, Payne CS, et al. Myocardial protection with postconditioning is not enhanced by ischemic preconditioning. Ann Thorac Surg 2004; 78:961-969.
99. Rock P, Yao Z. Ischemia reperfusion injury, preconditioning and critical illness. Curr Opin Anesth 2002; 16:139-146.
100. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285:H579-H588.
101. Opie LH. Preconditioning and metabolic anti-ischaemic agents. Eur Heart J 2003; 24:1854-1856.